Clinical Trials Browser

Phase 1/2 × Myelodysplastic Syndromes × Amsacrine × Clear all

NCT05807932 2024-05-01

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Phase 1/2 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic